AM251 Suppresses Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells

Tomoyo Yoshinaga1,2, Kenichiro Uwabe3, Shoichi Naito2

  • 1Laboratory of Biochemistry, Graduate School of Life Science, Hokkaido University, Sapporo, Japan.

Plos One
|December 10, 2016
PubMed

Insights

The synthetic lipid AM251 effectively suppresses kidney fibrosis by inhibiting epithelial-mesenchymal transition (EMT). This compound targets key transcription factors and signaling pathways without involving cannabinoid or G protein-coupled receptors.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pharmacology

Background:

  • Kidney fibrosis is a significant cause of kidney disease.
  • Epithelial-mesenchymal transition (EMT) in renal tubular cells drives kidney fibrosis.
  • Transforming growth factor-beta 1 (TGF-β1) is a key inducer of EMT.

Purpose of the Study:

  • To identify lipophilic compounds that suppress TGF-β1-induced EMT.
  • To investigate the mechanism of action of the identified compound AM251.
  • To explore the potential of AM251 as a therapeutic agent for kidney fibrosis.

Main Methods:

  • Screening of a lipid library (~200 lipids) for EMT suppressors.
  • Testing compounds in immortalized HK-2 and primary RPTEC cells.
  • Microarray analysis to identify affected genes and pathways.
  • Assessing effects on EMT markers (COL1A1, E-cadherin) and signaling pathways (SMAD2/3, p38 MAPK).

Main Results:

  • AM251 suppressed EMT, reducing collagen 1A1 (COL1A1) and increasing E-cadherin.
  • AM251's effects were independent of cannabinoid receptor type 1 (CB1) and G protein-coupled receptor 55 (GRP55).
  • AM251 inhibited EMT transcription factors (SNAIL1, FOSB, JUNB) and upstream signaling (SMAD2/3, p38 MAPK).

Conclusions:

  • AM251 is a novel suppressor of EMT and kidney fibrosis.
  • AM251 acts via inhibition of key EMT transcription factors and TGF-β signaling pathways.
  • AM251 holds promise for developing new therapeutic strategies against kidney fibrosis.